**This publication was selected as one of the SOT RASS Top 10 Best Papers Demonstrating an Application of Risk Assessment**
A physiologically based pharmacokinetic (PBPK) modeling approach can be a valuable tool used in the early stages of a chemical safety assessment program to optimize the design of longer-term animal toxicity studies or to interpret study results.
This proof of principle study, involving multiple test cases, demonstrates that a PBPK model can be developed as a research tool to integrate available absorption, distribution, metabolism, and excretion (ADME) data from shorter-term in vivo studies or in vitro assays to simulate longer term exposure, which can inform dose selection, dose spacing, or sample collection intervals in future whole animal studies. A PBPK model can also be used to interpret toxicity testing results, generate hypotheses on potential modes of action, or identify early mechanistic biomarkers. These capabilities can potentially reduce animal use in longer-term studies, as well as improve our understanding of the study outcomes by providing insight into the internal to external concentration (IEC) relationship.
Read full publication HERE.
Learn more about the HESI PBPK Committee HERE.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.